In this video we look at the thought of French Paleontologist, Cosmologist, WWI veteran and Jesuit Priest, Teilhard De Chardin, and his conceptions of the Omega Point and the Noosphere as articulated in his most significant work, The Phenomenon of Man.
Join us on Discord! / discord.
#integral #philosophy #evolution #consciousness #history #noosphere
What Is a Particle?
How the Quantum Eraser Rewrites the Past | Space Time | PBS Digital Studios.
https://www.youtube.com/watch?v=8ORLN_KwAgs.
https://www.patreon.com/Formscapes.
https://twitter.com/Nalhek_Morgan.
#integral #consciousness #philosophy #videoessay #quantum #quantumphysics #metaphysics #philosophyofscience
Data rates and volume for mobile communication are ever-increasing with the growing number of users and connected devices. With the deployment of 5G and 6G on the horizon, wireless communication is advancing to higher frequencies and larger bandwidths enabling higher speeds and throughput. Current micro-acoustic resonator technology, a key component in radiofrequency front-end filters, is struggling to keep pace with these developments. This work presents an acoustic resonator architecture enabling multi-frequency, low-loss, and wideband filtering for the 5G and future 6G bands located above 3 GHz. Thanks to the exceptional performance of these resonators, filters for the 5G n77 and n79 bands are demonstrated, exhibiting fractional bandwidths of 25% and 13%, respectively, with low insertion loss of around 1 dB. With its unique frequency scalability and wideband capabilities, the reported architecture offers a promising option for filtering and multiplexing in future mobile devices.
Stettler, S., Villanueva, L.G. Suspended lithium niobate acoustic resonators with Damascene electrodes for radiofrequency filtering. Microsyst Nanoeng 11, 131 (2025). https://doi.org/10.1038/s41378-025-00980-w.
Precision and personalized medicine for disease management necessitates real-time, continuous monitoring of biomarkers and therapeutic drugs to adjust treatment regimens based on individual patient responses. This study introduces a wearable Microneedle-based Continuous Biomarker/Drug Monitoring (MCBM) system, designed for the simultaneous, in vivo pharmacokinetic and pharmacodynamic evaluation for diabetes. Utilizing a dual-sensor microneedle and a layer-by-layer nanoenzyme immobilization strategy, the MCBM system achieves high sensitivity and specificity in measuring glucose and metformin concentrations in skin interstitial fluid (ISF). Seamless integration with a smartphone application enables real-time data analysis and feedback, fostering a pharmacologically informed approach to diabetes management. The MCBM system’s validation and in vivo trials demonstrate its precise monitoring of glucose and metformin, offering a tool for personalized treatment adjustments. Its proven biocompatibility and safety suit long-term usage. This system advances personalized diabetes care, highlighting the move towards wearables that adjust drug dosages in real-time, enhancing precision and personalized medicine.
Real-time monitoring of drugs and biomarkers is essential for personalized diabetes care. Here, the authors present a wearable microneedle sensor system enabling simultaneous in vivo monitoring of glucose and metformin in interstitial fluids for personalized medicine.
(Toronto, Sept. 27, 2022) – Scientists at the Krembil Brain Institute, part of the University Health Network, have proposed a new mechanistic model (AD2) for Alzheimer’s, looking at it not as a brain disease, but as a chronic autoimmune condition that attacks the brain.
This novel research is published today, in Alzheimer’s & Dementia.
“We don’t think of Alzheimer’s as fundamentally a disease of the brain. We think of it as a disease of the immune system within the brain,” says Dr. Donald Weaver, co-Director of the Krembil Brain Institute and author of the paper.
Alzheimer’s disease, the most common form of dementia, impacts more than 50 million people around the world, with a new person being diagnosed every three seconds. Yet, despite more than 200 clinical trials in the past 30 years, there are no disease modifying therapeutics to prevent, halt or treat Alzheimer’s.
(Circa 2022 the immune function and immune molecules have been focused on recently making immunotherapy targets interesting consdering they can help remove plaques)
